



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,603	11/21/2003	T. Shantha Raju	PI1096R1C1	3279
9157	7590	11/02/2009	EXAMINER	
GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080			SCHWADRON, RONALD B	
		ART UNIT	PAPER NUMBER	
		1644		
		MAIL DATE		DELIVERY MODE
		11/02/2009		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/719,603	Applicant(s) RAJU, T. SHANTHA
	Examiner Ron Schwadron, Ph.D.	Art Unit 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-9 and 25-29 is/are pending in the application.
- 4a) Of the above claim(s) 7-9 and 27 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-6,25,26,28,29 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ . | 6) <input type="checkbox"/> Other: _____ . |

1. Claims 1-6,25,26,28,29 are under consideration.
2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. The rejection of claims 1-6,25,26,28,29 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9,20,35,37,39,41,43 of copending Application No. 10/744844 is withdrawn in view of the amended claims now present in 10/744844.

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. The rejection of claims 1-6,25,26,28,29 under 35 U.S.C. 103(a) as being unpatentable over Kumpel et al. in view of Maras et al. (US Patent 5,834,251) as elaborated in the previous Office action is withdrawn.

6. Claims 1-6,25,26,28,29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mattes (US Patent 4,859,449) in view of Kumpel et al. and Maras et al. (US Patent 5,834,251).

Mattes teaches therapeutic antibodies with terminal galactose oligosaccharides and the uses/advantages of such antibodies (see abstract, column 6, penultimate paragraph, column 8, last paragraph and claims 1,10,39). G2 antibodies have the maximum number of terminal galactose oligosaccharides. Mattes teaches a kit containing such antibodies (see column 13, first two paragraphs) wherein the antibody is present in a container with a label and wherein the composition present in said kit is a pharmaceutical composition as per recited in the claims. Mattes teaches the use of any IgG antibody (see column 4, third paragraph) wherein IgG1 is one of the art known isotypes of human IgG. Mattes do not teach that the antibodies are of the degree of purity recited in the claims. Kumpel et al. teach human monoclonal antibodies wherein substantially all of the oligosaccharide found on said antibody is G2 (see Table 1, columns 1-3, and page 149, column 1, first incomplete paragraph). The antibody 2B6 disclosed in Table 1 is an IgG1 antibody (see page 144, second column). Kumpel et al. teach that antibodies with substantially all G2 oligosaccharide have increased lysis of target cells in comparison to the same antibody which is produced in a manner that results in low levels of G2 (see Figure 3). Maras et al. teach that B-1,4 Galactosyltransferase can be used to modify the oligosaccharide profile on a glycoprotein (see columns 12 and 16). Kumpel et al. teach that said enzyme is involved in the production of G2 oligosaccharides (see abstract). A routineer would have used the method of Maras et al. to produce a more highly purified version of the G2 oligosaccharide containing antibody to further characterize the role of said oligosaccharides in effector function and to produce an antibody with even greater effector function. It would have been *prima facie* obvious to one of ordinary skill in the art to have created the claimed invention because Mattes teaches therapeutic

antibodies with terminal galactose oligosaccharides and the uses/advantages of such antibodies whilst Kumpel et al. teach that antibodies with substantially all G2 oligosaccharide have increased lysis of target cells in comparison to the same antibody which is produced in a manner that results in low levels of G2 and Maras et al. teach that B-1,4 Galactosyltransferase can be used to modify the oligosaccharide profile on a glycoprotein (e.g. to produce highly pure G2 oligosaccharide glycoproteins). One of ordinary skill in the art would have been motivated to do the aforementioned because Mattes teaches therapeutic antibodies with terminal galactose oligosaccharides and the uses/advantages of such antibodies whilst Kumpel et al. teach that antibodies with substantially all G2 oligosaccharide have increased lysis of target cells in comparison to the same antibody which is produced in a manner that results in low levels of G2. A routineer would have used the method of Maras et al. to produce a more highly purified version of the G2 oligosaccharide containing antibody for use in the method taught by Mattes.

Regarding applicants comments as they apply to this new ground of rejection, Mattes teaches therapeutic antibodies with terminal galactose oligosaccharides and the uses/advantages of such antibodies (see abstract, column 6, penultimate paragraph, column 8, last paragraph and claims 1,10,39) whilst Kumpel et al. teach human monoclonal antibodies wherein substantially all of the oligosaccharide found on said antibody is G2 and that antibodies with substantially all G2 oligosaccharide have increased lysis of target cells in comparison to the same antibody which is produced in a manner that results in low levels of G2 (see Figure 3).

7. No claim is allowed.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is (571)272-0851. The examiner can normally be reached on Monday-Thursday 7:30-6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ron Schwadron/
Ron Schwadron, Ph.D.
Primary Examiner
Art Unit 1644